Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Youths - Birth - 17
  • North Carolina
  • Winston Salem


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • ICOLLAB FOR Children With Medical Complexity
    NCT03978468
    Condition:   Children With Medical Complexity
    Interventions:   Other: Interagency Collaboration (ICollab);   Other: Usual Care
    Sponsor:   Wake Forest University Health Sciences
    Recruiting
  • Epigenetic and Metabolomic Changes in Childhood Cancer Survivors
    NCT03866707
    Condition:   Childhood Cancer
    Interventions:   Other: One-time blood draw;   Other: Evaluation of CpG methylation;   Other: Metabolomic analysis
    Sponsor:   Wake Forest University Health Sciences
    Recruiting
  • Eucrisa for Atopic Dermatitis
    NCT03250663
    Condition:   Mild to Moderate Atopic Dermatitis
    Interventions:   Behavioral: Online Treatment response;   Drug: EUCRISA
    Sponsor:   Wake Forest University Health Sciences
    Recruiting
  • Vitamin D Deficiency and Dysautonomia
    NCT03032328
    Conditions:   Vitamin D Deficiency;   Orthostatic Intolerance;   Nausea
    Intervention:   Dietary Supplement: vitamin D supplement
    Sponsor:   Wake Forest University Health Sciences
    Recruiting
  • Volunteering as an Intervention to Reduce Depression Among Adolescents
    NCT03816215
    Conditions:   Depression;   Adolescent Behavior;   Depressive Symptoms
    Intervention:   Behavioral: Volunteer experience
    Sponsor:   Wake Forest University Health Sciences
    Recruiting
  • Measuring Health Related Quality of Life in AYAs
    NCT03482778
    Conditions:   Oncology;   Quality of Life;   PROM
    Intervention:  
    Sponsors:   Wake Forest University Health Sciences;   Feinberg School of Medicine, Northwestern University
    Recruiting
  • Medical Data Collection in the Formation of Precision Oncology Registry
    NCT03874065
    Condition:   Cancer
    Intervention:   Other: Medical Chart Review
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting
  • Second Line Gemcitabine and Nivolumab in Treating Participants With Metastatic Small Cell Lung Cancer
    NCT03662074
    Conditions:   Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Interventions:   Drug: Gemcitabine;   Biological: Nivolumab
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting
  • Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients
    NCT03571620
    Condition:   Atopic Dermatitis
    Interventions:   Drug: Q301 Cream;   Drug: Vehicle
    Sponsor:   Qurient Co., Ltd.
    Recruiting
  • Effectiveness of KeraStat Gel for Improved Cosmesis of Partial Thickness Burns
    NCT03564795
    Condition:   Partial-thickness Burn
    Interventions:   Device: KeraStat Gel;   Device: Silver Sulfadiazine
    Sponsors:   KeraNetics, LLC;   Wake Forest University;   United States Department of Defense
    Recruiting
  • Palliative Radiation Therapy in Reducing Pain in Patients With Bone Metastasis
    NCT02699697
    Conditions:   Malignant Neoplasm;   Metastatic Malignant Neoplasm in the Bone;   Pain
    Interventions:   Radiation: External Beam Radiation Therapy;   Radiation: Palliative Radiation Therapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting
  • MICU Recovery Clinic
    NCT02560129
    Conditions:   Critical Illness;   Sepsis;   Respiratory Failure;   ARDS
    Intervention:   Other: Questionnaires, Physical and Cognitive Function
    Sponsor:   Wake Forest University Health Sciences
    Recruiting
  • Establishment of Cell Culture Systems From Discarded Operating Room Tissue
    NCT01000077
    Condition:   Surgery
    Intervention:  
    Sponsors:   Wake Forest University Health Sciences;   United States Department of Defense
    Recruiting
  • Studies of the Variable Phenotypic Presentations of Rapid-Onset Dystonia Parkinsonism and Other Movement Disorders
    NCT00682513
    Conditions:   Dystonia;   Parkinsonism
    Intervention:  
    Sponsors:   University of California, Davis;   National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting
  • Clinician Burnout and Social Determinants
    NCT04070456
    Condition:   Burnout, Professional
    Intervention:   Other: Tablet-based SDH tool
    Sponsor:   Wake Forest University Health Sciences
    Recruiting
  • RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction
    NCT04091672
    Conditions:   Full-thickness Skin Defects;   Degloving Injuries;   Crush Injuries;   Laceration of Skin;   Surgical Wound;   Skin Cancer;   Cellulitis;   Infection;   Necrotizing Fasciitis;   Gun Shot Wound
    Interventions:   Device: Autografting with RECELL overspray;   Procedure: Conventional Autografting
    Sponsor:   Avita Medical
    Recruiting
  • Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
    NCT02663297
    Conditions:   Hodgkin Disease;   Lymphoma;   Lymphoma, Non-Hodgkin;   Immune System Diseases;   Immunoproliferative Disorders;   Lymphatic Diseases;   Lymphoproliferative Disorders;   Neoplasms;   Neoplasms by Histologic Type
    Intervention:   Drug: ATLCAR.CD30 cells
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting
  • Flourish™ Pediatric Esophageal Atresia
    NCT03615495
    Conditions:   Esophageal Atresia;   Digestive System Abnormalities;   Esophageal Disorders Congenital
    Intervention:   Device: Flourish Pediatric Esphogeal Atresia device
    Sponsor:   Cook Research Incorporated
    Recruiting
  • Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers
    NCT03673462
    Condition:   Healthy Volunteers (Meningococcal Infection)
    Interventions:   Biological: Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine (MenACYW conjugate vaccine);   Biological: Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®);   Biological: Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b Vaccine;   Biological: Pneumococcal 13-valent Conjugate Vaccine;   Biological: Rotavirus Vaccine;   Biological: Hepatitis B Vaccine;   Biological: Measles, Mumps, and Rubella Virus Vaccine;   Biological: Varicella Virus Vaccine
    Sponsor:   Sanofi Pasteur, a Sanofi Company
    Recruiting
  • A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies
    NCT03650452
    Conditions:   Epilepsy;   Dravet Syndrome;   Lennox-Gastaut Syndrome
    Interventions:   Drug: TAK-935;   Drug: Placebo
    Sponsors:   Takeda;   Ovid Therapeutics Inc.
    Recruiting
  • Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
    NCT03601637
    Condition:   Cystic Fibrosis
    Interventions:   Drug: LUM;   Drug: IVA
    Sponsor:   Vertex Pharmaceuticals Incorporated
    Recruiting
  • Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease
    NCT03395639
    Condition:   Cardiac Disease
    Interventions:   Drug: Edoxaban;   Drug: Standard of Care (SOC)
    Sponsor:   Daiichi Sankyo, Inc.
    Recruiting
  • MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)
    NCT03230838
    Conditions:   Complicated Urinary Tract Infection;   Pyelonephritis
    Interventions:   Drug: Ceftolozane;   Drug: Tazobactam;   Drug: Meropenem
    Sponsor:   Merck Sharp & Dohme Corp.
    Recruiting
  • Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide
    NCT03185819
    Condition:   Depressive Disorder, Major
    Interventions:   Drug: Intranasal Placebo;   Drug: Midazolam Placebo Solution;   Drug: Midazolam;   Drug: Esketamine
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • Developmental Impact of NICU Exposures (DINE)
    NCT03061890
    Condition:   Prematurity
    Intervention:  
    Sponsors:   Albert Einstein College of Medicine;   National Institutes of Health (NIH)
    Recruiting
  • Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy
    NCT02914314
    Condition:   Epilepsy
    Intervention:   Drug: perampanel
    Sponsor:   Eisai Inc.
    Recruiting
  • Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement
    NCT02828358
    Conditions:   Acute Leukemia of Ambiguous Lineage;   B Acute Lymphoblastic Leukemia;   Mixed Phenotype Acute Leukemia
    Interventions:   Drug: Azacitidine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Prednisolone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • BAX 855 Previously Untreated Patient (PUP)
    NCT02615691
    Condition:   Hemophilia A
    Intervention:   Biological: PEGylated Recombinant Factor VIII
    Sponsor:   Baxalta now part of Shire
    Recruiting
  • Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
    NCT02521493
    Conditions:   Acute Myeloid Leukemia;   Down Syndrome;   Myelodysplastic Syndrome;   Myeloid Leukemia Associated With Down Syndrome;   Myeloproliferative Neoplasm
    Interventions:   Drug: Asparaginase;   Drug: Asparaginase Erwinia chrysanthemi;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone;   Drug: Mitoxantrone Hydrochloride;   Drug: Thioguanine
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
    NCT02369653
    Conditions:   Lymphoma;   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Apixaban;   Other: No systemic anticoagulant prophylaxis
    Sponsors:   Bristol-Myers Squibb;   Pfizer
    Recruiting
  • Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
    NCT02176967
    Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Neuroblastoma
    Interventions:   Drug: Carboplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
    NCT03845296
    Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
    Intervention:   Drug: Rucaparib
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications
    NCT03381196
    Condition:   Influenza A
    Interventions:   Drug: Pimodivir 600 mg;   Drug: Placebo;   Other: SOC Treatment
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)
    NCT02819635
    Condition:   Ulcerative Colitis (UC)
    Interventions:   Drug: Placebo;   Drug: Updacitinib (ABT-494)
    Sponsor:   AbbVie
    Recruiting
  • DOSE Trial of Opioid Sparing Effect
    NCT03938857
    Conditions:   Dexmedetomidine;   Mechanical Ventilation Complication;   Critically Ill
    Interventions:   Drug: Fentanyl;   Drug: Dexmedetomidine
    Sponsors:   Duke University;   National Institutes of Health (NIH);   Johns Hopkins University;   Intermountain Health Care, Inc.;   Vanderbilt University Medical Center
    Recruiting
  • An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
    NCT03921528
    Conditions:   Spinal Muscular Atrophy;   Spinal Muscular Atrophy Type 3;   Spinal Muscular Atrophy Type 2;   SMA;   Neuromuscular Diseases;   Muscular Atrophy;   Atrophy;   Muscular Atrophy, Spinal;   Neuromuscular Manifestations
    Intervention:   Biological: SRK-015
    Sponsor:   Scholar Rock, Inc.
    Recruiting
  • A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL Therapy
    NCT03914625
    Conditions:   B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma;   Down Syndrome
    Interventions:   Drug: Asparaginase Erwinia chrysanthemi;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Mercaptopurine Oral Suspension;   Drug: Methotrexate;   Drug: Prednisolone;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Study in Children With Hyperkalaemia Between Birth and <18 Years of Age to Evaluate Doses of Sodium Zirconium Cyclosilicate (SZC) for Correction of Hyperkalaemia and Effectiveness of Same Dose to Maintain Normokalaemia.
    NCT03813407
    Condition:   Hyperkalaemia
    Interventions:   Drug: Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level;   Drug: Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1);   Drug: Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2);   Drug: Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3);   Drug: Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase
    Sponsor:   AstraZeneca
    Recruiting
  • Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
    NCT03533582
    Conditions:   Childhood Hepatocellular Carcinoma;   Childhood Malignant Liver Neoplasm;   Hepatoblastoma;   Hepatocellular Malignant Neoplasm, Not Otherwise Specified;   SMARCB1 Gene Mutation
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Fluorouracil;   Drug: Gemcitabine;   Drug: Irinotecan;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Other: Patient Observation;   Drug: Sorafenib;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma
    NCT03126916
    Conditions:   Ganglioneuroblastoma;   INRG Stage L2;   INRG Stage M;   INRG Stage MS;   Neuroblastoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Dexrazoxane;   Drug: Dexrazoxane Hydrochloride;   Biological: Dinutuximab;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Radiation: Iobenguane I-131;   Drug: Isotretinoin;   Drug: Melphalan;   Drug: Melphalan Hydrochloride;   Biological: Sargramostim;   Procedure: Therapeutic Conventional Surgery;   Drug: Thiotepa;   Drug: Topotecan;   Drug: Topotecan Hydrochloride;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
    NCT03067181
    Conditions:   Childhood Extracranial Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Germ Cell Tumor;   Malignant Germ Cell Tumor;   Malignant Ovarian Teratoma;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage I Ovarian Teratoma AJCC v6 and v7;   Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
    Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma
    NCT03057626
    Conditions:   Recurrent Neuroblastoma;   Stage 2A Neuroblastoma;   Stage 2B Neuroblastoma;   Stage 3 Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
    NCT03007147
    Conditions:   B Acute Lymphoblastic Leukemia;   BCR-ABL1 Fusion Protein Expression;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Dexrazoxane Hydrochloride;   Drug: Doxorubicin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University of Milano Bicocca
    Recruiting
  • Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
    NCT02724579
    Conditions:   CTNNB1 Gene Mutation;   Medulloblastoma;   Wnt Positive
    Interventions:   Drug: Cisplatin;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Drug: Lomustine;   Radiation: Radiation Therapy;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
    NCT02723994
    Condition:   Leukemia
    Interventions:   Drug: Ruxolitinib;   Drug: Asparaginase Erwinia Chrysanthemi;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Incyte Corporation;   Children's Oncology Group
    Recruiting
  • Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
    NCT02567435
    Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma
    Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)
    NCT04052425
    Condition:   Non-segmental Vitiligo
    Interventions:   Drug: Ruxolitinib cream;   Drug: Vehicle
    Sponsor:   Incyte Corporation
    Recruiting
  • Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation
    NCT03904134
    Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes;   Non-hodgkin Lymphoma;   Hodgkin Lymphoma;   Acquired Aplastic Anemia;   Sickle Cell Disease
    Intervention:   Other: Donor Search Prognosis Score
    Sponsors:   Center for International Blood and Marrow Transplant Research;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network;   National Marrow Donor Program;   Medical College of Wisconsin
    Recruiting
  • A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma
    NCT03769090
    Condition:   Asthma
    Interventions:   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg;   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg;   Combination Product: Albuterol sulfate metered-dose inhaler 180 μg
    Sponsor:   Bond Avillion 2 Development LP
    Recruiting
  • ACURATE IDE: Safety and Efficacy Study of Acurate Valve for Transcatheter Aortic Valve Replacement
    NCT03735667
    Condition:   Aortic Stenosis
    Interventions:   Device: ACURATE neo2™ Transfemoral TAVR System;   Device: Medtronic CoreValve TAVR System;   Device: Edwards SAPIEN 3 TAVR System
    Sponsor:   Boston Scientific Corporation
    Recruiting
  • A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis
    NCT03653026
    Condition:   Ulcerative Colitis (UC)
    Interventions:   Drug: Upadacitinib (ABT-494);   Drug: Placebo
    Sponsor:   AbbVie
    Recruiting
  • A Phase 2, Prospective, Interventional, Open-Label, Multi-Site, Extension Study to Assess the Long-Term Safety and Tolerability of TAK-935 (OV935) as Adjunctive Therapy in Patients With Rare Epilepsy
    NCT03635073
    Condition:   Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome, Dup15q Syndrome, CDKL5 Deficiency Disorder
    Intervention:   Drug: TAK-935
    Sponsors:   Takeda;   Ovid Therapeutics Inc.
    Recruiting
  • LCI-HEM-SCD-ST3P-UP-001: The Sickle Cell Trevor Thompson Transition Project (ST3P-UP Study)
    NCT03593395
    Condition:   Sickle Cell Disease
    Interventions:   Other: Peer Mentoring [PM];   Other: Structured Education Based Transition Program STE
    Sponsors:   Ifeyinwa (Ify) Osunkwo MD MPH;   Patient-Centered Outcomes Research Institute
    Recruiting
  • Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.
    NCT03529045
    Conditions:   Epilepsy;   Seizures;   Drug Resistant Epilepsy
    Intervention:   Device: Vagus Nerve Stimulation (VNS) Therapy
    Sponsor:   LivaNova
    Recruiting
  • A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus
    NCT03517722
    Condition:   Lupus Erythematosus, Systemic
    Interventions:   Drug: Placebo;   Drug: Ustekinumab (approximately 6 mg/kg);   Drug: Ustekinumab 90 mg
    Sponsor:   Janssen Research & Development, LLC
    Recruiting
  • Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
    NCT03493685
    Condition:   Focal Segmental Glomerulosclerosis
    Interventions:   Drug: sparsentan;   Drug: irbesartan
    Sponsor:   Retrophin, Inc.
    Recruiting
  • An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
    NCT03467958
    Condition:   Crohn Disease
    Intervention:   Drug: Ozanimod
    Sponsor:   Celgene
    Recruiting
  • A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease
    NCT03464097
    Condition:   Crohn Disease
    Interventions:   Drug: Ozanimod;   Other: Placebo
    Sponsor:   Celgene
    Recruiting
  • Evaluation of Safety and Efficacy of Brimonidine Tartrate Ophthalmic Suspension
    NCT03450629
    Conditions:   Open Angle Glaucoma;   Ocular Hypertension
    Interventions:   Drug: Brimonidine Tartrate Ophthalmic Suspension;   Drug: Brimonidine Tartrate Ophthalmic Solution
    Sponsor:   Sun Pharma Advanced Research Company Limited
    Recruiting
  • Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
    NCT03440385
    Condition:   Crohn Disease
    Interventions:   Drug: Ozanimod;   Other: Placebo
    Sponsor:   Celgene
    Recruiting
  • Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
    NCT03422822
    Condition:   Dermatitis, Atopic
    Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
    Sponsor:   Pfizer
    Recruiting
  • A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease
    NCT03251118
    Conditions:   Inflammatory Bowel Diseases;   Crohn's Disease;   Ulcerative Colitis;   Indeterminate Colitis
    Intervention:  
    Sponsor:   Target PharmaSolutions, Inc.
    Recruiting
  • A Study of AeroVanc for the Treatment of MRSA Infection in CF Patients
    NCT03181932
    Conditions:   MRSA;   Cystic Fibrosis
    Interventions:   Drug: Vancomycin inhalation powder;   Drug: Placebo inhalation powder
    Sponsor:   Savara Inc.
    Recruiting
  • A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
    NCT03112603
    Condition:   Graft-versus-host Disease (GVHD)
    Interventions:   Drug: Ruxolitinib;   Drug: Extracorporeal photopheresis (ECP);   Drug: Low-dose methotrexate (MTX);   Drug: Mycophenolate mofetil (MMF);   Drug: mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus);   Drug: Infliximab;   Drug: Rituximab;   Drug: Pentostatin;   Drug: Imatinib;   Drug: Ibrutinib
    Sponsor:   Incyte Corporation
    Recruiting
  • Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome
    NCT02834793
    Condition:   Lennox-Gastaut Syndrome (LGS)
    Interventions:   Drug: Placebo;   Drug: Perampanel
    Sponsor:   Eisai Inc.
    Recruiting
  • Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
    NCT02830477
    Condition:   Hemophilia A, Congenital
    Intervention:   Biological: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973
    Sponsor:   Bayer
    Recruiting
  • A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)
    NCT02815891
    Conditions:   Nonalcoholic Fatty Liver;   Nonalcoholic Steatohepatitis
    Intervention:  
    Sponsor:   Target PharmaSolutions, Inc.
    Recruiting
  • An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US
    NCT02783651
    Condition:   Relapsed/Refractory Acute Lymphoblastic Leukemia
    Intervention:   Other: Other
    Sponsor:   Amgen
    Recruiting
  • A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease
    NCT02663908
    Condition:   Prostate Cancer
    Interventions:   Drug: Degarelix;   Drug: Leuprolide
    Sponsors:   Ferring Pharmaceuticals;   Memorial Sloan Kettering Cancer Center;   Duke Clinical Research Institute
    Recruiting
  • A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    NCT02576431
    Condition:   Solid Tumors Harboring NTRK Fusion
    Intervention:   Drug: BAY2757556 (Larotrectinib, Vitrakvi)
    Sponsor:   Bayer
    Recruiting
  • EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)
    NCT02240784
    Condition:   Acute Hepatic Porphyria
    Intervention:  
    Sponsor:   Alnylam Pharmaceuticals
    Recruiting
  • Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
    NCT02392078
    Conditions:   Metastatic Brain Tumor;   Primary Brain Tumor;   Epileptic/Seizure Foci
    Intervention:   Device: NeuroBlate System
    Sponsor:   Monteris Medical
    Recruiting
  • Phenotype, Genotype & Biomarkers in ALS and Related Disorders
    NCT02327845
    Conditions:   Amyotrophic Lateral Sclerosis;   Frontotemporal Dementia;   Primary Lateral Sclerosis;   Hereditary Spastic Paraplegia;   Progressive Muscular Atrophy;   Multisystem Proteinopathy
    Intervention:  
    Sponsors:   University of Miami;   National Institute of Neurological Disorders and Stroke (NINDS);   National Center for Advancing Translational Science (NCATS);   St. Jude Children's Research Hospital;   ALS Association
    Recruiting
  • Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement
    NCT02202434
    Condition:   Aortic Stenosis
    Interventions:   Device: Lotus Valve System;   Device: CoreValve/Evolut R Transcatheter Aortic Valve Replacement System;   Device: LOTUS Edge Valve System
    Sponsor:   Boston Scientific Corporation
    Recruiting
  • Longitudinal Study of the Porphyrias
    NCT01561157
    Conditions:   Acute Porphyrias;   Cutaneous Porphyrias
    Intervention:  
    Sponsor:   Icahn School of Medicine at Mount Sinai
    Recruiting
  • Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
    NCT01790152
    Conditions:   Hodgkin Lymphoma in Remission;   Leukemia in Remission;   Lymphoblastic Lymphoma;   Osteosarcoma;   Recurrent Leukemia;   Recurrent Lymphoma;   Recurrent Malignant Neoplasm
    Interventions:   Other: Assessment of Therapy Complications;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting
  • Product Surveillance Registry
    NCT01524276
    Conditions:   Cardiac Rhythm Disorders;   Urological Disorders;   Neurological Disorders;   Cardiovascular Disorders;   Digestive Disorders;   Intracranial Aneurysm;   Mechanical Circulatory Support
    Intervention:  
    Sponsor:   Medtronic
    Recruiting
  • Nephrotic Syndrome Study Network
    NCT01209000
    Conditions:   Minimal Change Disease (MCD);   Membranous Nephropathy;   Glomerulosclerosis, Focal Segmental
    Intervention:   Procedure: Kidney Biopsy
    Sponsors:   University of Michigan;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   The NephCure Foundation
    Recruiting
  • Neuropsychological and Behavioral Testing in Younger Patients With Cancer
    NCT00772200
    Conditions:   Childhood Malignant Neoplasm;   Cognitive Side Effects of Cancer Therapy
    Interventions:   Procedure: Cognitive Assessment;   Other: Quality-of-Life Assessment
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC